ArticleCancer medicine2015
Clinical benefit in recurrent glioblastoma from adjuvant NovoTTF-100A and TCCC after temozolomide and bevacizumab failure: a preliminary observation.
Article in Cancer medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 6 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- Efficacy and safety of tumor treating fields (TTF) combined with chemotherapy versus chemotherapy only in the treatment of glioblastoma: a systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
- Stereotactic radiosurgery for recurrent high-grade gliomas: a systematic review.Journal of neuro-oncology · 2025Pooled it
- Efficacy and safety of tumor-treating fields in recurrent glioblastoma: a systematic review and meta-analysis.Acta neurochirurgica · 2022Pooled it
- Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of cytotoxic chemotherapy and other cytotoxic therapies in the management of progressive glioblastoma in adults.Journal of neuro-oncology · 2022Guideline
- A systematic review of tumor treating fields therapy for high-grade gliomas.Journal of neuro-oncology · 2020Pooled it
- Tumor-treating fields as a fourth treating modality for glioblastoma: a meta-analysis.Acta neurochirurgica · 2018Pooled it
- Recent advances in Tumor Treating Fields (TTFields) therapy for glioblastoma.The oncologist · 2025Review
- Heterogeneity and individualized treatment of microenvironment in glioblastoma (Review).Oncology reports · 2023Article
- Article
- Meta-Analysis of Modulated Electro-Hyperthermia and Tumor Treating Fields in the Treatment of Glioblastomas.Cancers · 2023Review
- Anti-cancer mechanisms of action of therapeutic alternating electric fields (tumor treating fields [TTFields]).Journal of molecular cell biology · 2022Review
- Review
- Novel Concepts of Glioblastoma Therapy Concerning Its Heterogeneity.International journal of molecular sciences · 2021Review
- Tumor-Treating Fields for the treatment of glioblastoma: a systematic review and meta-analysis.Neuro-oncology practice · 2021Review
- Management of non-compressible torso hemorrhage: An update.Chinese journal of traumatology = Zhonghua chuang shang za zhi · 2021Review
- A contemporary update on glioblastoma: molecular biology, current management, and a vision towards bio-adaptable personalized care.Journal of neuro-oncology · 2021Review
- The Value of Tumor Treating Fields in Glioblastoma.Journal of Korean Neurosurgical Society · 2020Article
- Identification of 3 subpopulations of tumor-infiltrating immune cells for malignant transformation of low-grade glioma.Cancer cell international · 2019Article
- Article
- Direct-Current Electric Field Distribution in the Brain for Tumor Treating Field Applications: A Simulation Study.Computational and mathematical methods in medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The NovoTTF-100A is a device that emits alternating electric fields and it is approved for the treatment of recurrent glioblastoma. It works by perturbing tumor cells during mitosis as they enter anaphase leading to aneuploidy, asymmetric chromosome segregation and cell death with evidence of increased immunogenicity. Clinical trial data have shown equivalent efficacy when compared to salvage chemotherapies in recurrent disease. Responders were found to have had a lower dexamethasone usage and a higher rate of prior low-grade histology. We treated a series of patients with NovoTTF-100A and bevacizumab alone (n = 34) or in combination with a regimen consisting of 6-thioguanine, lomustine, capecitabine, and celecoxib (TCCC) (n = 3). Compared to the former cohort, the latter cohort exhibited a trend for prolonged overall survival, median 4.1 (0.3-22.7) months versus 10.3 (7.7-13.6) months respectively (P = 0.0951), with one experiencing an objective response with a 50% reduction in tumor size on magnetic resonance imaging despite possessing a larger tumor size at baseline and more severe neurologic dysfunction than the median for either group. These observations illustrate the possibility of improving survival and achieving a response in patients with end-stage recurrent glioblastoma by biasing the tumor toward anti-tumor immunologic response with a combination of NovoTTF-100A and TCCC, as well as the continuation of bevacizumab in order to limit dexamethasone use due to its global immunosuppressive effect on the patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.